Eyenovia (NASDAQ:EYEN) Earns Neutral Rating from HC Wainwright

Eyenovia (NASDAQ:EYEN)‘s stock had its “neutral” rating reiterated by equities researchers at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They currently have a $2.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 11.11% from the company’s previous close. HC Wainwright also issued estimates for Eyenovia’s FY2029 earnings at $1.40 EPS.

Other equities analysts have also recently issued research reports about the stock. Brookline Capital Management reaffirmed a “hold” rating on shares of Eyenovia in a research note on Friday, November 15th. William Blair reaffirmed a “market perform” rating on shares of Eyenovia in a report on Friday, November 15th. Finally, LADENBURG THALM/SH SH reiterated a “neutral” rating on shares of Eyenovia in a research report on Monday, November 18th.

Eyenovia Stock Performance

EYEN opened at $1.80 on Thursday. The business has a 50 day moving average price of $6.67 and a two-hundred day moving average price of $33.30. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.74 and a quick ratio of 0.55. The company has a market capitalization of $2.51 million, a price-to-earnings ratio of -2.47 and a beta of 1.24. Eyenovia has a 1-year low of $1.80 and a 1-year high of $205.60.

Eyenovia (NASDAQ:EYEN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($8.80) earnings per share for the quarter, beating the consensus estimate of ($10.40) by $1.60. Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same period last year, the business earned ($14.40) earnings per share. Research analysts predict that Eyenovia will post -0.52 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC raised its holdings in shares of Eyenovia by 36.6% during the third quarter. Geode Capital Management LLC now owns 557,994 shares of the company’s stock valued at $288,000 after acquiring an additional 149,471 shares during the period. Nations Financial Group Inc. IA ADV grew its position in Eyenovia by 78.6% during the 3rd quarter. Nations Financial Group Inc. IA ADV now owns 90,900 shares of the company’s stock worth $47,000 after purchasing an additional 40,000 shares in the last quarter. Finally, Financial Management Network Inc. acquired a new stake in Eyenovia during the 3rd quarter valued at $39,000. 25.84% of the stock is currently owned by institutional investors and hedge funds.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.